ATRX and cancer: We have previously shown that the IDH1 R132H mutation acts in the same pathway as the H3.3 G34R mutation in inhibiting KDM4B H3K9/K36 demethylase and promoting ALT telomere maintenance pathway in ATRX mutated cancers [53], a phenotype that necessitates the formation of ALT-associated PML bodies.